Ege University, Family Planning and Infertility Research and Practice Center, Izmir, Turkey.
Department of Obstetrics and Gynecology, Ege University Faculty of Medicine, Izmir, Turkey.
J Obstet Gynaecol. 2022 Apr;42(3):518-523. doi: 10.1080/01443615.2021.1931067. Epub 2021 Aug 12.
The aim of this study was to evaluate the effectiveness of controlled ovarian stimulation (COS) using the letrozole-supplemented stimulation protocol in breast cancer (BC) patients prior to their cancer treatment. Sixty-one BC patients (Stages 0-3) who were referred to a university IVF unit for fertility preservation (FP) and underwent embryo and/or oocyte cryopreservation between 2008 - 2020 were included in this retrospective study. Time intervals between breast surgery and initial fertility consultation (IFC)/completion of FP procedures were evaluated. COS outcomes were assessed and compared between the early follicular phase (EFP) and the random-start (RS) protocols. The patients' mean age was 33.3 ± 4.9 years. The mean time interval between breast surgery and IFC was 20.6 ± 11 (day, mean ± SD) and from IFC to completion of FP procedure was 14.7 ± 5.3. Overall, 9.1 ± 5.9 mature oocytes were obtained, with a peak serum oestradiol level of 388 ± 358 pg/mL. The number of oocytes obtained (11.5 ± 9.3 vs. 10.9 ± 6.9, = .9) and maturation rates (84.3 ± 17.5% vs. 89.2 ± 11.7, = .5) were not statistically different between the EPF and RS protocols. The study results support that oocyte or embryo freezing can be performed effectively in a limited time period with letrozole-supplemented COS protocols before the initiation of oncological treatments in breast cancer patients.Impact statement Currently, embryo and oocyte freezing are considered the most established fertility preservation (FP) methods for newly diagnosed cancer patients. This study reports the COS outcomes of newly diagnosed breast cancer patients for FP over a period of twelve years from a single IVF unit. The results support that a considerable number of oocytes can be harvested with letrozole-supplemented COS protocol, which appears to be an effective protocol for BC patients. There is a need for additional studies evaluating long-term follow-up of patients with their pregnancy outcomes.
本研究旨在评估在癌症治疗前使用来曲唑补充刺激方案对乳腺癌(BC)患者进行控制性卵巢刺激(COS)的有效性。本回顾性研究纳入了 2008 年至 2020 年间因生育力保存(FP)而被转诊至大学 IVF 中心并接受胚胎和/或卵母细胞冷冻保存的 61 例 BC 患者(0-3 期)。评估了乳腺癌手术与初始生育咨询(IFC)/FP 程序完成之间的时间间隔。评估并比较了早卵泡期(EFP)和随机起始(RS)方案的 COS 结果。患者的平均年龄为 33.3±4.9 岁。乳腺癌手术与 IFC 之间的平均时间间隔为 20.6±11(天,均值±标准差),IFC 至 FP 程序完成的时间间隔为 14.7±5.3。总体而言,获得了 9.1±5.9 个成熟卵母细胞,血清雌二醇水平峰值为 388±358pg/mL。EFP 和 RS 方案获得的卵母细胞数量(11.5±9.3 对 10.9±6.9,=0.9)和成熟率(84.3±17.5%对 89.2±11.7,=0.5)无统计学差异。研究结果支持在乳腺癌患者开始癌症治疗前的有限时间内,使用来曲唑补充 COS 方案有效地进行卵母细胞或胚胎冷冻保存。